For the quarter ending 2026-02-28, NRIX made $6.252M in revenue. -$87.174M in net income. Net profit margin of -1394.34%.
| Income Statement | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|---|
| Total revenue | 6.252 | 6* | 7.894 | 44.056 |
| Research and development | 84.137 | 70* | 86.12 | 78.096 |
| General and administrative | 14.61 | 12* | 13.159 | 14.282 |
| Total operating expenses | 98.747 | 82* | 99.279 | 92.378 |
| Loss from operations | -92.495 | -76* | -91.385 | -48.322 |
| Interest and other income, net | 5.321 | 6* | 4.964 | 5.618 |
| Loss before income taxes | - | -70* | -86.421 | -42.704 |
| Provision for income taxes | - | 0* | 0 | 0.76 |
| Net loss | -87.174 | -70 | -86.421 | -43.464 |
| Basic EPS | -0.79 | -0.757 | -1.03 | -0.52 |
| Diluted EPS | -0.79 | -0.757 | -1.03 | -0.52 |
| Basic Average Shares | 110,071,668 | 91,958,908 | 84,159,336 | 83,882,477 |
| Diluted Average Shares | 110,071,668 | 91,958,908 | 84,159,336 | 83,882,477 |
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)